drugset / Trial / NCT04615845
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells(DC) in patients with metastatic castration resistant prostate cancer (mCRPC)
Timeline
- Start
- 2021-06-21
- Primary completion
- 2022-02-15
- Completion
- 2022-02-15
Outcome
Outcome not reported
Stopped (Enrollment): “Difficult recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cellgram-DC-PC | Cell therapy | — | Subcutaneous |